Literature DB >> 1331272

Neuroendocrine-immune interactions associated with loss and restoration of immune system function in spinal cord injury and stroke patients.

J M Cruse1, R E Lewis, G R Bishop, W F Kliesch, E Gaitan.   

Abstract

Both natural and adaptive immune responses were shown to be strikingly decreased in initial blood samples from 34 spinal cord injury and stroke patients. NK-cell function decreased to 24.8% (mean) 2 weeks after spinal cord injury in previously healthy young adults whose control group revealed a mean NK-cell function of 48.7%. This was accompanied at 2 weeks by increased plasma ACTH (mean of 17.0 pg/ml from 17 patients compared to a mean of 11.2 pg/ml from 12 controls) and urine free cortisol levels (mean of 152.1 micrograms/24 h from 9 patients compared to 53.6 micrograms/24 h from 15 controls). T-cell function and/or activation decreased to below normal values within 3 months after injury as revealed by lymphocyte transformation that was 32.8% of normal at 3 months. T-cell activation diminished as shown by a mean IL-2 receptor level of 179.3 units/ml in patients compared to 328.2 units/ml in controls. Serial monitoring of NK- and T-cell function revealed that specific physical rehabilitation therapy over a period of 6 months after injury restored NK- and T-cell function to near normal levels in most patients. This improvement was accompanied by a parallel rise in the patient's functional independence measurement scores. Results suggest critical neuroendocrine-immune system interactions in the restoration of immune function. Cortisol levels reverted to normal after 6 months of rehabilitation. Limited data suggest that natural immune system depression, NK-cell function, persists in spinal cord injury patients not receiving rehabilitation therapy (mean NK-cell lysis of 10.3%; p < 0.01).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331272     DOI: 10.1007/bf02918615

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  8 in total

Review 1.  Production of peptide hormones and neurotransmitters by the immune system.

Authors:  J E Blalock
Journal:  Chem Immunol       Date:  1992

Review 2.  Signaling pathways of the neuroendocrine-immune network.

Authors:  T L Roszman; W H Brooks
Journal:  Chem Immunol       Date:  1992

Review 3.  Corticotropin-releasing hormone in humans.

Authors:  D N Orth
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

4.  Hormone specific regulation of natural killer cells by cortisol. Direct inactivation of the cytotoxic function of cloned human NK cells without an effect on cellular proliferation.

Authors:  D M Callewaert; V K Moudgil; G Radcliff; R Waite
Journal:  FEBS Lett       Date:  1991-07-08       Impact factor: 4.124

Review 5.  Noradrenergic and peptidergic innervation of lymphoid organs.

Authors:  S Y Felten; D L Felten; D L Bellinger; J A Olschowka
Journal:  Chem Immunol       Date:  1992

Review 6.  A molecular basis for bidirectional communication between the immune and neuroendocrine systems.

Authors:  J E Blalock
Journal:  Physiol Rev       Date:  1989-01       Impact factor: 37.312

Review 7.  Interactions between the neuroendocrine and immune systems: common hormones and receptors.

Authors:  D A Weigent; J E Blalock
Journal:  Immunol Rev       Date:  1987-12       Impact factor: 12.988

Review 8.  Neuroendocrine-immune interactions: immunoregulatory signals mediated by neurohumoral agents.

Authors:  J Cavagnaro; G A Waterhouse; R M Lewis
Journal:  Year Immunol       Date:  1988
  8 in total
  18 in total

Review 1.  Immune dysfunction and chronic inflammation following spinal cord injury.

Authors:  D J Allison; D S Ditor
Journal:  Spinal Cord       Date:  2014-11-04       Impact factor: 2.772

2.  Damage control in the nervous system: beware the immune system in spinal cord injury.

Authors:  Phillip Popovich; Dana McTigue
Journal:  Nat Med       Date:  2009-07       Impact factor: 53.440

3.  Spinal cord injury-induced immune deficiency syndrome enhances infection susceptibility dependent on lesion level.

Authors:  Benedikt Brommer; Odilo Engel; Marcel A Kopp; Ralf Watzlawick; Susanne Müller; Harald Prüss; Yuying Chen; Michael J DeVivo; Felix W Finkenstaedt; Ulrich Dirnagl; Thomas Liebscher; Andreas Meisel; Jan M Schwab
Journal:  Brain       Date:  2016-01-10       Impact factor: 13.501

4.  Anti-alpha4beta1 integrin antibody induces receptor internalization and does not impair the function of circulating neutrophilic leukocytes.

Authors:  Jennifer C Fleming; Feng Bao; Gediminas Cepinskas; Lynne C Weaver
Journal:  Inflamm Res       Date:  2010-03-07       Impact factor: 4.575

Review 5.  Immune system-neuroendocrine dysregulation in spinal cord injury.

Authors:  J M Cruse; J C Keith; M L Bryant; R E Lewis
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

6.  CD11d integrin blockade reduces the systemic inflammatory response syndrome after spinal cord injury.

Authors:  Feng Bao; Arthur Brown; Gregory A Dekaban; Vanessa Omana; Lynne C Weaver
Journal:  Exp Neurol       Date:  2011-07-19       Impact factor: 5.330

7.  B cells and autoantibodies: complex roles in CNS injury.

Authors:  Daniel P Ankeny; Phillip G Popovich
Journal:  Trends Immunol       Date:  2010-08-04       Impact factor: 16.687

Review 8.  Exercise recommendations for individuals with spinal cord injury.

Authors:  Patrick L Jacobs; Mark S Nash
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  Impaired antibody synthesis after spinal cord injury is level dependent and is due to sympathetic nervous system dysregulation.

Authors:  Kurt M Lucin; Virginia M Sanders; T Bucky Jones; William B Malarkey; Phillip G Popovich
Journal:  Exp Neurol       Date:  2007-06-02       Impact factor: 5.330

Review 10.  Low-grade inflammation and spinal cord injury: exercise as therapy?

Authors:  Eduardo da Silva Alves; Valdir de Aquino Lemos; Francieli Ruiz da Silva; Fabio Santos Lira; Ronaldo Vagner Thomathieli Dos Santos; João Paulo Pereira Rosa; Erico Caperuto; Sergio Tufik; Marco Tulio de Mello
Journal:  Mediators Inflamm       Date:  2013-03-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.